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STATE OF THE ART: CONCISE REVIEW
Lung Cancer in Octogenarians
Elizabeth M. Blanchard, MD,* Konstantinos Arnaoutakis, MD,† and Paul J. Hesketh, MD‡
Background: Lung cancer has progressively become a disease of
older people, with the median age at diagnosis now exceeding 70
years. Octogenarians represent a rapidly growing proportion of
patients diagnosed with lung cancer and can present distinct chal-
lenges. Nevertheless, current literature that has set the evidence-
based standards of care in this disease does not include significant
numbers of patients older than 80 years.
Methods: We have compiled and reviewed the available literature
on the specific management and treatment of lung cancer in patients
older than 80 years.
Results: Retrospective series suggest that surgery is safe and effec-
tive in treating early-stage non-small cell lung cancer in selected
patients older than 80 years. There is minimal data to support the use
of adjuvant chemotherapy in this group. In addition, no data exist on
the use of combined chemotherapy and radiotherapy for locally
advanced disease. In advanced or metastatic disease, similar to
younger elderly populations, single-agent chemotherapy is feasible
and seems to offer benefit in terms of symptoms and outcomes.
Small cell lung cancer in this population is not well characterized,
but small studies suggest symptom improvement and prolongation
of survival with the use of chemotherapy.
Conclusion: Based on retrospective series, octogenarians with lung
cancer can derive benefit from many of the treatment modalities
used for younger patients including surgery for early-stage disease
and single-agent chemotherapy for advanced disease. More elderly
specific trials are needed to better refine treatment decisions and
improve the care of lung cancer in this group.
Key Words: Non-small cell lung cancer, Small cell lung cancer,
Octogenarian.
(J Thorac Oncol. 2010;5: 909–916)
Given the progressive aging of the Western populations,lung cancer, the leading cause of cancer-related mortal-
ity has increasingly become a disease of older individuals. In
the United States, more than two of every three patients with
lung cancer are older than 65 years.1 In addition, the median
age at the time of diagnosis now exceeds 70 years.1
In recent years, a growing body of data has begun to
emerge, including some prospective trials, to help guide
clinicians in choosing appropriate treatment options for the
older patients with lung cancer, usually defined as patients
aged 70 years or older. Despite these encouraging efforts,
information on treatment outcome in the “very elderly” (pa-
tients aged 80 years or older) remains very limited. Octoge-
narians represent one of the most rapidly growing groups of
patients with lung cancer, accounting for 14% of all patients2
and 24% of all lung cancer deaths in the United States in
2006.3 It is estimated that the number of patients with lung
cancer older than 85 years of age will quadruple by the
middle of this century.4 In this review, available information
from the literature on the treatment of patients aged 80 years
or older with lung cancer has been retrieved to attempt to
provide some guidance on appropriate treatment options for
this patient population.
SEARCH STRATEGY
Articles relevant to the topic were obtained by Ovid
Medline searches using the following search terms: “lung
cancer” and “lung neoplasm” paired with “octogenarian,”
“over 80,” “very elderly,” and “aged.” No date limits were
applied, and only articles written in English were retrieved. In
addition, articles were identified from major journals of
thoracic oncology including Journal of Thoracic Oncology
and Journal of Clinical Oncology using the same terms.
Abstracts from the proceedings of the American Society of
Clinical Oncology meetings were also searched.
PATTERNS OF CARE
A number of studies have documented that the proportion
of patients receiving active treatment for lung cancer decreases
with advancing age.5,6 Few of the earlier patterns of care studies
have evaluated the subgroup of patients older than 80 years.
Several recent reports provide very important information on
this patient population. An analysis of the National Cancer
Institute Surveillance, Epidemiology and End Results (SEER)
database from 1988 to 20032 compared patients with lung cancer
aged 80 years or older with those aged 70–79 years and younger
than 70 years and found that patients older than 80 years were
less likely to be treated with local therapy and had decreased
survival compared with both younger groups. Overall outcomes
for patients who underwent surgical therapy or radiation were
similar across the three age distributions. No data were available
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from the SEER database on chemotherapy, but an earlier anal-
ysis of a linked SEER-Medicare database of patients with lung
cancer older than 65 years, demonstrated that patients older than
75 years were less likely to receive chemotherapy.7 In a series
from the Veterans Administration8 more than 20,000 patients
aged 70–84 and 85–115 years with non-small cell lung
cancer (NSCLC) were compared, including 1347 patients
with lung cancer older than 85 years. There was a significant
difference in treatment rates between the age groups includ-
ing patients undergoing surgery (2.7% versus 0.5%, p 
0.01), radiation (4.8% versus 3.3%, p  0.05), and chemo-
therapy (9.0% versus 2.9%, p  0.01) comparing the 70–84
and 85–115 age groups, respectively. Comorbidity was in-
creased in the older age group for some conditions (dementia,
frailty, and heart disease) but decreased for others (hyperten-
sion, hyperlipidemia, and diabetes).
Indeed, clinicians treating octogenarians face the chal-
lenge of varying degrees of comorbidity and frailty. Assessing
functionality in elderly patients with cancer is of critical impor-
tance both to be able to gauge the tolerability and appropriate-
ness of therapy and to yield potential prognostic information.
Commonly used tools such as the Eastern Cooperative Group
(ECOG) performance status (PS) scale often fall short in elderly
patients. Many attempts have been made to develop a system
that is both comprehensive enough to define physiologic age,
functionality, and potential vulnerabilities of elderly patients but
feasible enough to use in clinical practice. The Charlson scale9 is
a measure of comorbidity and has been studied as a tool to better
gauge treatment tolerability and prognosis with conflicting re-
sults. In an analysis of the Miles study, which demonstrated that
single-agent chemotherapy was as effective as a nonplatinum
doublet in patients older than 70 years, the Charlson scale did
not correlate with prognosis; however, an expanded assessment
of activities of daily living in a scale termed instrumental
activities of daily living did.10 The instrumental activities of
daily living incorporates activities such as managing finances
and household chores. The comprehensive geriatric assessment
is considered as an inclusive assessment of functionality but
difficult to incorporate into routine use and may not correlate
well with toxicity in patients with advanced lung cancer.11 The
European Organization for the Research and Treatment of Can-
cer has adopted the Vulnerable Elders Survey-13 questionnaire
for its clinical trials involving older adults.12 Although not
designed specifically for oncology, this tool is composed of 13
questions involving age, physical function, and ability to man-
age finances and household chores. A score of 3 or greater
identified a group of elders with four times the risk of death or
functional decline during an ensuing 2-year period. It is impor-
tant that elderly patients undergo a functional assessment at the
onset of a cancer diagnosis, and it is equally important that
clinical trials involving elderly patients incorporate such tools
into their design.
NON-SMALL CELL LUNG CANCER
Early-Stage Disease
Surgery
Surgery remains the mainstay of treatment for early-stage
NSCLC regardless of age.13 The belief that patients older than
80 years have limited life expectancy or that radiation therapy
and observation yield similar results to surgery in early-stage
disease have influenced low resection rates in this population.2,14
Nevertheless, advances in surgical techniques, anesthesia, and
postoperative care have made surgical lung resection a safer
procedure than it was in the past.
Several series specifically in octogenarians have dem-
onstrated the feasibility of pulmonary resection for lung
cancer in patients aged 80 years and older (Tables
1–3),13,15–41 especially when they are carefully selected. All
the published studies evaluating and treating fit octogenarians
are retrospective and are subject to selection bias. In the
United States, the largest retrospective series from the Mayo
Clinic reviewed 379 patients aged 80 years and older who
underwent pulmonary resection with curative intent for
NSCLC.16 Complications occurred in 48% of patients, most
commonly atrial fibrillation and retained secretions requiring
bronchoscopy. Other complications included pneumonia
(7%), new home oxygen requirement (7%), air leak more
than 5 days (7%), postoperative mechanical ventilation (6%),
and myocardial infarction (4%). The operative mortality of
all patients, defined as death within 30 days of the procedure
or during the same hospital admission, was 6.3%. The post-
operative mortality of the 240 patients who underwent lobec-
tomy was 5%. Other smaller studies (Table 1) have shown
mortality rates between 0% and 17.6%. Similar results were
seen in a retrospective study using the Nationwide Inpatient
Sample between 1994 and 2003 analyzing 24,804 octogenar-
ians. The operative mortality for lung resection was 6.7%
compared with 3.7% for the age group 65–69 years (p 
0.0001).42 The higher risk of mortality compared with
younger patients in these studies underscores the importance
of carefully selecting the appropriate surgical candidates.
Survival data from the SEER database, based on pa-
tients of all ages who were diagnosed with NSCLC between
1988 and 2001, show that survival rates for stages I and II
were 56% and 34%,43 respectively. In the published studies
of octogenarians (Table 1), the 5-year survival rates for
resected disease vary significantly from 24 to 57% likely
because of small sample size, incomplete follow-up, and
selection bias.
Extent of pulmonary resection may influence outcomes
in octogenarians,17 though data are likely confounded by T
stage. Many propose that right pneumonectomy needs to be
avoided in octogenarians.13,25,44 Pneumonectomy rates are
low among octogenarians (Table 1), and therefore, it is
difficult to draw firm conclusions. The role of sublobar
pulmonary resections remains a controversial area for both
elderly and nonelderly patients with early-stage lung cancer
though some evidence is emerging specifically for octogenar-
ians.32,45 Analysis of the SEER data of 14,555 patients with
stage I or II NSCLC from 1992 to 1997 showed that the
benefit of a lobectomy was not evident for patients older than
71 years compared with limited resections.46 Okami et al.41
found no difference in 5-year survival in octogenarians who
underwent lobectomy (245 patients) compared with limited
resection (122 patients) (p value of 0.9499). In a study from
the University of Pittsburgh, lobectomy was compared with
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segmentectomy for patients with stage I NSCLC. Segmen-
tectomy was associated with reduced mortality (7.8% versus
2.8%) and improved 3-year survival (p 0.02) in a subgroup
of 99 octogenarians.47
Several series36,40,48 indicate that video-assisted tho-
racic surgery (VATS) is feasible and probably safer than open
thoracotomy, although they have not been compared directly
in a prospective randomized fashion. In the largest retrospec-













Mortality 5-yr OS VATS
Dominguez-Ventura
et al.16
379 Lobectomy (63.3%) 6.6 93.4% I (67.1%) 6.3% NM 9.2%
Okami et al.41 367 Lobectomy (66.8%) 0 0 I (60.9%) NM NM
Wada et al.15 225 NM NM NM NM 2.2 NM
McVay et al.18 159 Lobectomy (96%) 2 NM I (100%) 1.8 NM 100
Suemitsu et al.19 146 Lobectomy (54.1%) 0.7 100 I/II (75.3%) NM NM
Brokx et al.13 124 Lobectomy (70%) 12 NM I (64%) 4 24
Ikeda et al.20 73 Lobectomy (63.3%) 0 86 I (76%) 4.1 57.4a
Dillman et al.21 70 Lobectomy (84%) 1 NM NM 1.4 NM
Brock et al.22 68 Lobectomy (69%) 1.5 80.9 I (60.3%) 8.8 34
Port et al.23 61 Lobectomy (75.4%) 6.5 100 I (44%) 1.6 38
Mun and Kohno.24 55 Lobectomy (67.2%) 0 NM I (80%) 3.6 NM 100
Pagni et al.25 54 Lobectomy (79.6%) 1.8 NM I (76%) 3.7 43
Aoki et al.26 49 Lobectomy (100%) 0 44.8 I (100%) 2 52.5a
Chida et al.27 48 Lobectomy (89.5%) 4.2 100b I (62.5%) NM NM
Bolukbas et al.28 47 Lobectomy (66%) 4.3 100 I (38.3%) 4.3 NM
Matsuoka et al.29 40 Lobectomy (60%) 0 40 I (87.5%) 0 56.9 85c
Mizuguchi et al.30 40 Lobectomy (80%) 0 100b I (60%) 0 42 27.5
Naunheim et al.31 37 Lobectomy (70.2%) 13.5 NM I (95%) 16 NM
Ginsberg and
Rubinstein32
37 Lobectomy and wedge
resection (63.3%)
8.1 NM NM 8.1 NM
Muraoka et al.33 33 Sublobar resection (69.6%) 0 33 I (100%) 0 NM
Shirakusa et al.34 33 Lobectomy (63.6%) 9.1 100 I (54.5%) 0 55
Osaki et al.35 33 Lobectomy (66.6%) 9.1 NM I (48%) 3 32.3
Koizumi et al.36 32 Lobectomy (100%) 0 59.4 I (68.8%) 12.5 46.6d 53
Hope et al.37 20 Lobectomy (60%) 15 NM I (50%) 10 NM
Hanagiri et al.38 18 Lobectomy (50%) 0 NM I (50%) 0 NM
Harvey et al.39 17 NM NM NM NM 17.6 42
McKenna40 9 Lobectomy (77.7%) 11.1 100 I (100%) 0 NM 100
a Patients with stage I disease only.
b Includes both complete mediastinal dissection and sampling.
c Includes muscle sparing posterolateral thoracotomy.
d For those who underwent VATS.
OS, overall survival; MLN, mediastinal lymph node evaluation at the time of the operation; NM, not mentioned; VATS, video-assisted thoracic surgery.








Brokx et al.13 1989–2004 225 I and II Unknown 20 3 Not reported
Gauden and Tripcony52 1985–1992 31 I 50 Gya 49b 0% deaths from radiation
complications
Hayakawa et al.51 1976–1996 30 I–III 60 Gy 28 4 0% pneumonitis requiring
hospitalization
Zachariah et al.53 1988–1995 21 59.4–66 Gyc Not reported Not reported 0% treatment interruption
due to pneumonitis
a Minimum tumor dose.
b At 30 mo of follow-up.
c Range of radiation dose in a group of patients, which included 11 octogenarians.
NSCLC, non-small cell lung cancer.
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tive evaluation of 159 octogenarians18 undergoing VATS for
resection of clinical stage I disease, the morbidity rate was
18%, and the mortality rate was 1.8%. All patients had a
tumor size of less than 5 cm, no chest wall or mediastinal
invasion, no endobronchial tumor seen at bronchoscopy, and
a negative mediastinoscopy. A smaller study with 55 patients
evaluating clinical stage I patients aged 80 years and older
undergoing VATS showed similar, although somewhat in-
creased, postoperative morbidity and mortality rates of 25.6%
and 3.6%, respectively.24
It is difficult to draw definitive conclusions from retro-
spective studies; however, in the absence of a better thera-
peutic modality, surgery continues to be the most important
therapy to improve outcomes in patients older than 80 years
with early-stage NSCLC. There are no prospective trials
evaluating the use of more limited resections in patients older
than 80 years, and this question is the subject of several
ongoing phase III trials in a variety of age groups. Therefore,
at this time, lobectomy is the preferred surgery for octoge-
narians based on the available data. More extensive surgeries
require careful evaluation of the risks and benefits. Although
specific evidence is lacking, limited surgeries may have a role
in octogenarians with limited survival or possibly for patients
with small, peripherally located tumors, who are at significant
risk of postoperative complications.
Radiation
Although surgery remains the mainstay of early-stage
NSCLC treatment, radiation therapy is generally reserved for
patients who cannot tolerate a surgical resection, because it is
associated with inferior outcomes. However, radiation is safe
in older persons and can improve outcomes compared with
best supportive care alone.49 Multiple studies that include
octogenarians50–52 have shown that some patients with stage
I disease experience long-term survival with definitive radi-
ation therapy. Zachariah et al.53 evaluated 37 octogenarians
with lung cancer who received radiation treatment (dose
range, 59–66 Gy). More than 90% of patients completed
therapy, and there was no grade 3 or 4 esophagitis. Morita et
al.,54 in a subgroup analysis of 149 patients with NSCLC who
received radiation with curative intent, found that although
patients older than 80 years had similar rates of complete
response, the 3- and 5-year actuarial survival rates were lower
than that of younger patients with survival rates in octoge-
narians at 3 and 5 years of 15.4% and 7.7% versus 38.2% and
25.2% in younger patients (p  0.035).
Despite the inferior outcomes of radiation therapy com-
pared with surgery and possibly compared with younger
patients, radiation therapy is feasible and should be consid-
ered for octogenarians with early-stage NSCLC who cannot
or do not want to undergo surgery.
Stereotactic radiosurgery is increasingly being used in
NSCLC, though no specific trials have focused on octoge-
narians. In two published series in medically inoperable
patients with node negative, T1 or T2 tumors, the Kaplan-
Meier local control rates were 95% at 2 years55 and 92% at 3
years.56 Based on this early evidence, stereotactic radiosur-
gery is safe, more effective than standard external beam
radiotherapy and may be comparable with surgery. Avoiding
the morbidity, recovery, and potential mortality of a thoracic
surgery would be advantageous for a vulnerable population
such as octogenarians. Prospective trials are currently ongo-
ing in both medically inoperable patients and in comparison
with surgery in operable patients.
Adjuvant Chemotherapy
Adjuvant chemotherapy in resected early-stage NSCLC
has shown a survival benefit in several studies57,58 and in a
meta-analysis.59 To date, there are no adjuvant studies per-
formed solely with octogenarian patients, and results can only
be extrapolated from retrospective subset analyses from com-
pleted trials. The LACE meta-analysis included five major
studies investigating the use of platinum-based adjuvant ther-
apy for patients with resected NSCLC. This analysis demon-
strated that efficacy was not different in patients older than 60
years compared with younger patients, even though older
patients received lower doses and fewer cycles of chemother-
apy.60 However, only two of the trials, JBR1060 and the Big
Lung Trial,61 included patients older than 75 years and the
number of these patients were only 23 and eight, respectively.
TABLE 3. Studies of Patients Older than 80 yr with Advanced NSCLC Treated with Chemotherapy
Trial Study Type
No. of
Patients Treatment Outcomes Toxicity
Altundag et al.70 Retrospective 66 Multiple different first-line
regimens, 43% platinum
doublets
PFS and OS were similar in
patients older than 80 yr
compared with patients
younger than 80 yr
No difference in hematologic
or nonhematologic toxicity
Chen et al.69 Prospective, single arm 20 Vinorelbine plus gemcitabine Time to progression of 5.5 mo,
median survival of 10 mo,
and percent surviving at
1 yr of 37.5%




Hesketh et al.71 Subgroup analysis 49 Vinorelbine/docetaxel Overall survival in patients
with a PS of 0–1 was 11
and 7 mo in patients
younger than 80 yr and
older than or equal to
80 yr, respectively
Similar rates of grade 3/4
hematologic toxicity in
patients older and younger
than 80 yr
PFS, progression-free survival; OS, overall survival; NSCLC, non-small cell lung cancer; PS, performance status.
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In a separate analysis of JBR10 done by the National Cancer
Institute of Canada, a significant benefit of adjuvant chemo-
therapy in patients aged 65 to 75 years was found, though it
failed to show a survival benefit in the limited number of
patients older than 75 years.60
Thus, at present, there are no data to support the use of
adjuvant chemotherapy in patients older than 75 years,
though individual decisions should be made on a case by case
basis after a discussion of the risks, potential benefits, and
available data. Future studies are needed to define better
tolerated therapies in this group that are also effective in the
adjuvant setting.
Locally Advanced Disease
There are very little data on the outcomes of concurrent
chemoradiation therapy in octogenarians with locally ad-
vanced NSCLC. A joint analysis62 of the North Central
Cancer Treatment Group (NCCTG) 90-24-51 and NCCTG
90-24-52 studies evaluating the subset of older patients (aged
65 years or older) treated with radiation versus chemoradia-
tion found improved outcomes in the group treated with
combined therapy but with increased toxicity in that group as
well. Only six octogenarians were included in these studies,
and no specific analysis of this group was performed. Clinical
trials in this group of patients are urgently needed possibly
with incorporation of newer, better tolerated agents.
Advanced Disease
Chemotherapy is known to increase survival and im-
prove cancer-related symptoms in patients with advanced
NSCLC.63 The American College of Chest Physician guide-
lines for treatment of stage IV NSCLC,64 while recommend-
ing chemotherapy for select patients older than 70 years,
caution that the benefit of chemotherapy in patients older than
80 years is unknown and recommend instead a case by case
assessment (grade 2C). A number of recent prospective trials
have looked at specific chemotherapy regimens in patients
aged 70 years or older but have either included few patients
older than 80 years or have not provided any information on
this subgroup.65
Similarly, most of the recent pivotal trials in the general
population of patients with advanced NSCLC have included few
patients older than 80 years. ECOG 1594,66 a trial comparing
platinum doublets in NSCLC included only nine patients (1% of
those enrolled) who were aged 80 years or older. In a subgroup
analysis,67 patients aged 70–80 years seemed to do as well as
those younger than 70 years, though patients older than 80 years
seemed to do worse, with a median survival of 8.25 and 8.15
months in patients aged 70–80 years and younger than 70
years, respectively, whereas those aged 80 years or older had
a median survival of 4.2 months. ECOG 4599, which estab-
lished the use of bevacizumab in combination with carbopla-
tin and paclitaxel, included four patients older than 80 years
representing just 1.6% of the elderly cohort and less than 1%
of the study group as a whole.68
The limited available data on chemotherapy use in
patients aged 80 years or older consist of a few retrospective
analyses and a single prospective phase II trial. The latter trial
by Chen et al.69 evaluated the combination of vinorelbine and
gemcitabine in 20 patients older than 80 years with stage IIIB
or IV NSCLC (range, 80–88 years). The overall response
rate was 65%, and median survival was 10 months. Feasibil-
ity of treatment was assessed by the number of chemotherapy
cycles with most patients receiving two cycles and a median
number of cycles of four. Importantly, there was symptom
improvement, with more than half of patients noting im-
provement in lung cancer-related symptoms including pain,
dyspnea, cough, and hemoptysis.
In a retrospective series from MD Anderson,70 patients
aged 80 years and older with stage IV NSCLC or stage III
disease with a malignant effusion treated between 1997 and
2004 were compared with matched controls younger than 80
years. A total of 46 patients with a median age of 82 years
(range, 80–88 years) were compared with a matched control
group of younger patients with a median age of 65 years
(range, 28–79 years). Nearly half of the older patient group
was treated with platinum doublet therapy. Median survival
was not significantly different between the older and younger
groups at 10.7 (95% confidence interval: 6.87–18.2) months
in the older group compared with 9.8 (95% confidence
interval: 7.72–13.4) months in the younger group (p  0.43).
Both hematologic and nonhematologic toxicity were not
significantly different even when controlled for use of plati-
num-based chemotherapy.
Hesketh et al.71 reported on the outcomes of a subgroup
of patients older than 80 years combined from two trials with
similar eligibility requirements and treatment regimens. One
trial was conducted by the Southwest Oncology Group
(S0027) and the other was a multicenter investigator-initiated
trial (LUN 6). In this analysis, 49 patients aged 80 years or
older were compared with a control group of patients younger
than 80 years (median age 73 years) from S0027. Patients in
S0027 were treated with vinorelbine followed by docetaxel,
whereas the LUN 6 patients were treated with either weekly
or every 3-week docetaxel. Treatment administration was
similar in the two groups of S0027, with the group more than
or equal to 80 years completing a median of 4.5 cycles, and
patients younger than 80 years completing a median number
of five cycles. The most significant toxicity was grade 3 or 4
neutropenia, seen in about one-third of patients older than 80
years. There were two treatment-related deaths in the patient
group aged 80 years or older and three in the younger group.
Overall survival was not different between the groups broken
down by PS 0–1 and 2. In the original publication of LUN6,72
the weekly schedule seemed to be associated with a decreased
time to progression and better overall survival compared with
the every 3 week schedule in the subset of patients older than
80 years.
The use of molecularly targeted therapies has the po-
tential advantage of achieving clinical benefit with potentially
less adverse effects, therefore providing an appealing treat-
ment option in this age group. However, similar to chemo-
therapy, very little data with these agents exist. Ebi et al.73
looked at the use of gefitinib as initial treatment in 49 elderly
Japanese patients aged 75 years or older with inoperable
NSCLC in a phase II study. Although not designed specifi-
cally for octogenarians, the median age of the study popula-
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tion was 80 years with a range of 75–90 years. The overall
disease control rate was 59% with a 25% partial response rate
and a median survival of 10 months. Fifteen patients (30%)
experienced treatment-related adverse events, 13 patients
withdrew because of toxicity, and two treatment-related
deaths resulted from interstitial lung disease.
Although large studies that have defined the standard of
care in advanced NSCLC have not included a significant
proportion of octogenarians, smaller retrospective series
demonstrate the feasibility and possible benefit of chemother-
apy in this age group. Properly selected patients can be
counseled that chemotherapy has the potential to relieve
cancer-related symptoms, seems to be safe, and may offer a
survival benefit comparable with that of younger elderly
patients. As with younger elderly patients, the available
information is most supportive of single-agent chemotherapy.
Platinum doublet therapy can be considered for selected
patients, though it may be associated with increased toxicity
in elderly patients.64 In addition, the EGFR tyrosine kinase
inhibitors also seem to be a viable treatment option in patients
older than 80 years.
SMALL CELL LUNG CANCER
Little information is available in regards to the treat-
ment of small cell lung cancer (SCLC) in elderly patients,
particularly in patients older than 80 years. One retrospective
series74 of patients treated at the Royal Marsden Hospital
during a 20-year period compared patients in three age
groups: 70–74 years, 75–79 years, and 80 years and older.
The latter group consisted of 26 patients, who constituted 8%
of the population. The majority of the over 80 group had
limited stage disease (73%) and a PS of 1. Most patients were
treated with a platinum doublet with 12% receiving a cispla-
tin-based regimen, 46% receiving a carboplatin-based regi-
men, and the remainder (46%) treated with nonplatinum
single agents. Median survival in patients older than 80 years
who presented with limited stage disease was 62 weeks,
whereas those with extensive stage disease had a median
survival of 34 weeks. No formal comparison was done
between age groups, and no information was collected on
toxicity. Another smaller retrospective study75 looked specif-
ically at the 10 patients older than 80 years treated at a single
institution with both limited and extensive stage. Of the 10
patients, two were treated with supportive care, one patient
received both chemotherapy and radiation, six were treated
with carboplatin plus etoposide, and the remaining two were
treated with oral etoposide. All patients treated with active
chemotherapy achieved a partial response except one who
was not evaluable after receiving a higher than standard dose
of carboplatin. Median survival of patients with limited stage
disease was 358.5 days, extensive stage disease 188 days, and
for the two patients not treated with chemotherapy, less
than 60 days. The difference in survival between those
treated with chemotherapy and supportive care was statis-
tically significant (p  0.01). Notably, seven of the eight
patients treated with active therapy had a complete reso-
lution of cancer-related symptoms for a period of 4 weeks
or more, the remaining patient had partial improvement.
Half of the patients treated with combination therapy with
carboplatin plus etoposide experienced grade 3 or more
toxicity, whereas no grade 3 toxicity was reported in the
two patients treated with oral etoposide.
The intensive chemotherapy regimens typically used to
treat SCLC provide a particular challenge to those patients
older than 80 years. Although very little data exist on this
group of patients, chemotherapy may have a role in treating
cancer-related symptoms and prolonging survival in patients
who can tolerate such therapy. Patient selection is very
important and a frank discussion of toxicity should be a part
of the decision-making process.
CONCLUSION
Although categorizing patients by chronologic age
alone is to some degree arbitrary, looking at octogenarians as
a group provides some insight into the benefits and risks of
available treatments for the very elderly patient with lung
cancer. Much of the data presented is limited by small sample
size, selection bias, and the retrospective nature of the anal-
yses. In addition, although widespread agreement exists that
patient selection is important, no data exist on the optimal
methods to assess fitness in this group for surgery or chemo-
therapy.
Historically, elderly patients have not participated in
clinical trials in the same proportions as their younger coun-
terparts.76 Increasing the knowledge base regarding this im-
portant population of patients with lung cancer is best done
through prospective randomized trials, and elderly specific
trials may be more likely to include patients older than 80
years. In a comparison of NCCTG77 elderly specific trials and
nonage restricted trials, the difference in the number of
patients older than 80 years enrolled was significant, com-
prising 17% of the elderly specific trials, but only 3% of the
nonage restricted trials (p  0.0008).
Despite the general lack of rigorous evidence regarding
treatment in octogenarians, several conclusions can be drawn
by examining the available body of literature of octogenari-
ans with lung cancer. Surgery seems to be the optimal
treatment for octogenarians with early-stage NSCLC and can
be done safely and is associated with outcomes that compare
favorably to other “younger elderly.” Radiation as primary
therapy remains a viable option for octogenarians who cannot
undergo surgery, as is the case with other age groups. No data
supporting the use of adjuvant chemotherapy after surgery
currently exist for octogenarians. No data are available on the
role of combined chemotherapy and radiation for locally
advanced disease. Decisions regarding therapy in these in-
stances is left to individual clinician and patient discussion of
available evidence in younger patients, as well as the balance
of risks and potential benefits. Advanced NSCLC is currently
incurable in all age groups, but chemotherapy and EGFR
inhibitors seem to be safe with similar toxicity profiles to
those seen with younger elderly patients. In addition, treat-
ment may decrease cancer-related symptoms and prolong
survival in fit octogenarians. Single-agent therapy is best
supported by available evidence. Although very little data
exist for octogenarians with SCLC, there are very small series
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that indicate that therapy is safe in selected patients and may
be of benefit in terms of relieving symptoms and improving
outcomes.
Future progress in defining appropriate treatment op-
tions for the rapidly growing population of the “very elderly”
will require carefully designed prospective trials in which
important prognostic variables such as PS and comorbidities
are fully accounted.
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